Over the past few decades, the incidence of thyroid cancer, which was once a relatively uncommon aspect of oncology, has significantly increased worldwide. This tendency makes opening of new horizons, and finding new modalities for both its diagnosis and therapy all the more crucial. The concept of theranostics in thyroid cancer has shown potential in individualizing treatments, tailoring therapies to the specific molecular characteristics of the patient's cancer.
Key words: N/A
|
